Literature DB >> 9224908

Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response.

M Maes1, R Verkerk, E Vandoolaeghe, F Van Hunsel, H Neels, A Wauters, P Demedts, S Scharpé.   

Abstract

Serum total tryptophan and the five competing amino acids (CAA), i.e., valine, leucine, tyrosine, phenylalanine, and isoleucine were determined in 35 major depressed subjects of whom 27 with treatment resistant depression (TRD), and 15 normal controls. Twenty-five of the depressed subjects had repeated measurements of the amino acids both before and after antidepressive treatment. The following immune-inflammatory variables were assayed in the above subjects: serum zinc (Zn), total serum protein (TSP), albumin (Alb), transferrin (Tf), iron (Fe), high-density lipoprotein cholesterol (HDL-C), number of peripheral blood leukocytes, and the CD4+/CD8+ T cell (T-helper/T-suppressor) ratio. Serum tryptophan and the tryptophan/CAA ratio were significantly lower in major depressed subjects than in normal controls. The tryptophan/CAA ratio was significantly lower in patients with TRD than in patients without TRD and normal controls. There were no significant alterations in any of the amino acids upon successful therapy. There were significant correlations between serum tryptophan and serum Zn, TSP, Alb, Tf, Fe, and HDL-C (all positive), and number of leukocytes and the CD4+/CD8+ T-cell ratio (all negative). The tryptophan/CAA ratio was significantly and negatively related to the number of leukocytes and the CD4+/CD8+ T-cell ratio. The results suggest that (a) TRD is characterized by lower availability of serum tryptophan; (b) the availability of tryptophan may remain decreased despite clinical recovery; and (c) the lower availability of tryptophan is probably a marker of the immune-inflammatory response during major depression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224908     DOI: 10.1007/bf03033069

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  44 in total

1.  Alterations in iron metabolism and the erythron in major depression: further evidence for a chronic inflammatory process.

Authors:  M Maes; J Van de Vyvere; E Vandoolaeghe; T Bril; P Demedts; A Wauters; H Neels
Journal:  J Affect Disord       Date:  1996-09-09       Impact factor: 4.839

2.  Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine.

Authors:  A Słuzewska; J K Rybakowski; M Laciak; A Mackiewicz; M Sobieska; K Wiktorowicz
Journal:  Ann N Y Acad Sci       Date:  1995-07-21       Impact factor: 5.691

3.  Changes on recovery in the concentrations of tryptophan and the biogenic amine metabolites in the cerebrospinal fluid of patients with affective illness.

Authors:  G W Ashcroft; I M Blackburn; D Eccleston; A I Glen; W Hartley; N E Kinloch; M Lonergan; L G Murray; I A Pullar
Journal:  Psychol Med       Date:  1973-08       Impact factor: 7.723

4.  The effects of glucocorticoids on the availability of L-tryptophan and tyrosine in the plasma of depressed patients.

Authors:  M Maes; C Schotte; S Scharpé; M Martin; P Blockx
Journal:  J Affect Disord       Date:  1990-02       Impact factor: 4.839

Review 5.  Evidence for an immune response in major depression: a review and hypothesis.

Authors:  M Maes
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1995-01       Impact factor: 5.067

6.  Concentration and microheterogeneity glycophorms of alpha-1-acid glycoprotein in major depressive disorder.

Authors:  A Sluzewska; J K Rybakowski; M Sobieska; K Wiktorowicz
Journal:  J Affect Disord       Date:  1996-07-08       Impact factor: 4.839

Review 7.  Tryptophan to competing amino acids ratio in depressive disorder: relation to efficacy of antidepressive treatments.

Authors:  S E Møller
Journal:  Acta Psychiatr Scand Suppl       Date:  1985

8.  Hypozincemia in depression.

Authors:  M Maes; P C D'Haese; S Scharpé; P D'Hondt; P Cosyns; M E De Broe
Journal:  J Affect Disord       Date:  1994-06       Impact factor: 4.839

9.  Relationships between lower plasma L-tryptophan levels and immune-inflammatory variables in depression.

Authors:  M Maes; H Y Meltzer; S Scharpé; E Bosmans; E Suy; I De Meester; J Calabrese; P Cosyns
Journal:  Psychiatry Res       Date:  1993-11       Impact factor: 3.222

View more
  15 in total

Review 1.  The unknown mechanism of the overtraining syndrome: clues from depression and psychoneuroimmunology.

Authors:  Lawrence E Armstrong; Jaci L VanHeest
Journal:  Sports Med       Date:  2002       Impact factor: 11.136

2.  Towards a new model and classification of mood disorders based on risk resilience, neuro-affective toxicity, staging, and phenome features using the nomothetic network psychiatry approach.

Authors:  Michael Maes; Juliana Brum Moraes; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; Ana Paula Michelin; Sandra Odebrecht Vargas Nunes
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

3.  The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke.

Authors:  Raf Brouns; Robert Verkerk; Tony Aerts; Didier De Surgeloose; Annick Wauters; Simon Scharpé; Peter P De Deyn
Journal:  Neurochem Res       Date:  2010-05-19       Impact factor: 3.996

Review 4.  A dialogue between the immune system and brain, spoken in the language of serotonin.

Authors:  Nicole L Baganz; Randy D Blakely
Journal:  ACS Chem Neurosci       Date:  2012-12-07       Impact factor: 4.418

5.  IgA/IgM responses to tryptophan and tryptophan catabolites (TRYCATs) are differently associated with prenatal depression, physio-somatic symptoms at the end of term and premenstrual syndrome.

Authors:  Chutima Roomruangwong; Buranee Kanchanatawan; Sunee Sirivichayakul; George Anderson; André F Carvalho; Sebastien Duleu; Michel Geffard; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-04-01       Impact factor: 5.590

6.  Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability.

Authors:  Sinan Guloksuz; Marieke Wichers; Gunter Kenis; Maurice G V M Russel; Annick Wauters; Robert Verkerk; Baer Arts; Jim van Os
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

7.  Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample.

Authors:  M Uddin; K C Koenen; A E Aiello; D E Wildman; R de los Santos; S Galea
Journal:  Psychol Med       Date:  2010-09-14       Impact factor: 7.723

8.  Tryptophan degradation in women with breast cancer: a pilot study.

Authors:  Debra E Lyon; Jeanne M Walter; Angela R Starkweather; Christine M Schubert; Nancy L McCain
Journal:  BMC Res Notes       Date:  2011-05-26

9.  Cytokines, neurophysiology, neuropsychology, and psychiatric symptoms.

Authors:  Markus J Schwarz
Journal:  Dialogues Clin Neurosci       Date:  2003-06       Impact factor: 5.986

10.  A Meta-Analysis of Oxidative Stress Markers in Depression.

Authors:  Tao Liu; Shuming Zhong; Xiaoxiao Liao; Jian Chen; Tingting He; Shunkai Lai; Yanbin Jia
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.